Notably, c‐Myc‐i7 demonstrated an exceptional approximately 40‐fold increase in effectiveness against prostate cancer (IC50 of 2.5 μM) when compared to 10058‐F4 (IC50 of 95.2 μM). Here, MYC is linked to prostate cancer.